Bausch Health might sell Bausch+Lomb, rather than spin it off

Quoting sources close to the matter, Bloomberg News reported last week that Bausch Health was currently exploring the possibility of a sale of its Bausch+Lomb’s eye care business unit, instead of the initially planned spin-off. Before being renamed as Bausch Health, Valeant Pharmaceuticals International had acquired Bausch & Lomb Holdings ...

To continue reading this article register now.

Already an Eyewear Intelligence subscriber? Sign in here.


Become a member today for full access from just €7,29 a week!

Buying a membership today will give you:

  • Unlimited access to - all insight and analysis available online
  • Our executive edition of Eyewear Intelligence (Digital Edition) - the must-read for all decision-makers in the industry
  • Weekly E-mail Briefing from the Chief Editor with the lastest analysis and most important industry developments
  • Case studies and best practices on business challenges
  • Guest chronicles, interviews, insights from industry experts and leaders that are shaping the future of the industry
  • Access to over 11,500 articles and analyses in the archive
  • Personal library to save articles and track your key content
  • Powerful search and intuitive navigation

Or sign-up for a trial month for just 9,90€. To continue reading this article register now.